EARLY TRIPLE NEGATIVE BREAST CANCER

Clinical trials for EARLY TRIPLE NEGATIVE BREAST CANCER explained in plain language.

Never miss a new study

Get alerted when new EARLY TRIPLE NEGATIVE BREAST CANCER trials appear

Sign up with your email to follow new studies for EARLY TRIPLE NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Withdrawn trial sought to boost Cancer-Killing power before surgery

Disease control Terminated

This study aimed to see if adding an experimental drug called boserolimab to standard pre-surgery treatment could better treat high-risk, early-stage triple-negative breast cancer. It planned to test the safety of this combination and measure how many patients had no detectable c…

Matched conditions: EARLY TRIPLE NEGATIVE BREAST CANCER

Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control

Last updated Mar 30, 2026 14:34 UTC

EARLY TRIPLE NEGATIVE BREAST CANCER

Get alerted when new EARLY TRIPLE NEGATIVE BREAST CANCER trials appear

Withdrawn trial sought to boost Cancer-Killing power before surgery